Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.
<h4>Objectives</h4>The objective of this study was to evaluate the cost-effectiveness of abatacept, tocilizumab, and tumor necrosis factor (TNF) inhibitors as compared with rituximab in Finnish rheumatoid arthritis patients, who have previously been treated with TNF inhibitors.<h4>...
| Päätekijät: | , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
Public Library of Science (PLoS)
2019-01-01
|
| Sarja: | PLoS ONE |
| Linkit: | https://doi.org/10.1371/journal.pone.0220142 |